{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:06:29Z","timestamp":1790485589510,"version":"4.1.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine: X"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.cytox.2019.100005","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T13:50:27Z","timestamp":1553694627000},"page":"100005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cytokines frequently implicated in myeloproliferative neoplasms"],"prefix":"10.1016","volume":"1","author":[{"given":"Yingying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.leu.2404946","article-title":"The history of myeloproliferative disorders: before and after Dameshek","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.cytox.2019.100005_b0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0015","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00432-015-1983-5","article-title":"Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973\u20132011","volume":"141","author":"Deadmond","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cytox.2019.100005_b0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"17","key":"10.1016\/j.cytox.2019.100005_b0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9464","key":"10.1016\/j.cytox.2019.100005_b0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cytox.2019.100005_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"issue":"25","key":"10.1016\/j.cytox.2019.100005_b0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.cytox.2019.100005_b0045","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0055","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.blre.2016.11.004","article-title":"Modeling myeloproliferative neoplasms: From mutations to mouse models and back again","volume":"31","author":"Morotti","year":"2017","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0065","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cytox.2019.100005_b0070","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cytox.2019.100005_b0080","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cytox.2019.100005_b0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and myeloproliferative neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytox.2019.100005_b0090","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/415024","article-title":"Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis","volume":"2015","author":"Desterke","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cytox.2019.100005_b0095","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/284706","article-title":"Impact of inflammation on myeloproliferative neoplasm symptom development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cytox.2019.100005_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/670580","article-title":"Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest","volume":"2015","author":"Mondet","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cytox.2019.100005_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/869242","article-title":"Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms","volume":"2015","author":"Hoermann","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cytox.2019.100005_b0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2017.01.006","article-title":"Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial","volume":"54","author":"Gowin","year":"2017","journal-title":"Leuk Res."},{"issue":"8","key":"10.1016\/j.cytox.2019.100005_b0115","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.cytox.2019.100005_b0120","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.humpath.2014.07.017","article-title":"Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature","volume":"45","author":"Vergara-Lluri","year":"2014","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajh.10258","article-title":"Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome","volume":"72","author":"Pullarkat","year":"2003","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.cytox.2019.100005_b0130","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.leukres.2013.09.001","article-title":"Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns","volume":"37","author":"Barcellini","year":"2013","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.cytox.2019.100005_b0135","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajh.22212","article-title":"Environmental, lifestyle, and familial\/ethnic factors associated with myeloproliferative neoplasms","volume":"87","author":"Anderson","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cytox.2019.100005_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2015.11.017","article-title":"Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"41","author":"S\u00f8rensen","year":"2016","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.cytox.2019.100005_b0150","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/CS20130497","article-title":"Cytokine networking of innate immunity cells: a potential target of therapy","volume":"126","author":"Striz","year":"2014","journal-title":"Clin. Sci."},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0155","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2215\/CJN.07590714","article-title":"Cytokines: names and numbers you should care about","volume":"10","author":"Holdsworth","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.cytox.2019.100005_b0160","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.leukres.2006.12.024","article-title":"Global cytokine analysis in myeloproliferative disorders","volume":"31","author":"Ho","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cytox.2019.100005_b0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"40","key":"10.1016\/j.cytox.2019.100005_b0170","doi-asserted-by":"crossref","first-page":"17031","DOI":"10.1073\/pnas.0905299106","article-title":"Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6\/IL-8 cytokine network","volume":"106","author":"Orjalo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0175","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.blre.2017.05.001","article-title":"Interleukin-1\u03b2 as emerging therapeutic target in hematological malignancies and potentially in their complications","volume":"31","author":"Arranz","year":"2017","journal-title":"Blood Rev."},{"issue":"24","key":"10.1016\/j.cytox.2019.100005_b0180","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2016-12-754994","article-title":"Targeting the interleukin-1 pathway in patients with hematological disorders","volume":"129","author":"de Mooij","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0609.1999.tb01845.x","article-title":"Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders","volume":"63","author":"Bourantas","year":"1999","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0190","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.cytox.2019.100005_b0195","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.cytox.2019.100005_b0200","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0210","first-page":"120","article-title":"Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation.Hematol Transfus","volume":"40","author":"Cacemiro","year":"2018","journal-title":"CellTher."},{"issue":"28","key":"10.1016\/j.cytox.2019.100005_b0215","doi-asserted-by":"crossref","first-page":"43974","DOI":"10.18632\/oncotarget.9949","article-title":"Crucial factors of the inflammatory microenvironment (IL-1\u03b2\/TNF-\u03b1\/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study","volume":"7","author":"Sollazzo","year":"2016","journal-title":"Oncotarget."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0220","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin. Immunol."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0225","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.24352","article-title":"Reduction in C-reactive protein indicates successful targeting of the IL-1\/IL-6 axis resulting in improved survival in early stage multiple myeloma","volume":"91","author":"Lust","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytox.2019.100005_b0235","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.iy.04.040186.000441","article-title":"The human interleukin-2 receptor","volume":"4","author":"Greene","year":"1986","journal-title":"Annu. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.cytox.2019.100005_b0240","first-page":"RA179","article-title":"Biological properties of interleukin 2 and its role in pathogenesis of selected diseases\u2013a review","volume":"14","author":"Olejniczak","year":"2008","journal-title":"Med. Sci. Monit."},{"issue":"8","key":"10.1016\/j.cytox.2019.100005_b0245","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytox.2019.100005_b0250","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.2001.tb03720.x","article-title":"Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma","volume":"941","author":"Foss","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"8","key":"10.1016\/j.cytox.2019.100005_b0255","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","article-title":"Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review","volume":"96","author":"Lin","year":"2017","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0925-5710(96)00554-3","article-title":"Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders","volume":"65","author":"Kawatani","year":"1997","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0265","article-title":"Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2R\u03b1","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjh.14770","article-title":"The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cytox.2019.100005_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine\u201340 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0280","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.cytox.2019.100005_b0285","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.cytox.2019.100005_b0295","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0300","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000354194","article-title":"Impact of interleukin-6 in hematological malignancies","volume":"40","author":"Burger","year":"2013","journal-title":"Transfus. Med. Hemother."},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0305","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.1991.tb04534.x","article-title":"Elevated serum interleukin-6 levels in patients with reactive thrombocytosis","volume":"79","author":"Hollen","year":"1991","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.cytox.2019.100005_b0310","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0022-2143(99)90154-3","article-title":"Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis","volume":"134","author":"Hsu","year":"1999","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.cytox.2019.100005_b0315","article-title":"Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities","author":"Kampan","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0320","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/mabs.1.5.9497","volume":"1","author":"Venkiteshwaran","year":"2009","journal-title":"Tocilizumab. MAbs."},{"issue":"7","key":"10.1016\/j.cytox.2019.100005_b0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-015-0453-1","article-title":"Clinical development of siltuximab","volume":"17","author":"Davis","year":"2015","journal-title":"Curr. Oncol. Rep."},{"issue":"13","key":"10.1016\/j.cytox.2019.100005_b0330","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytox.2019.100005_b0335","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytox.2019.100005_b0340","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","article-title":"Interleukin-8 in cancer pathogenesis, treatment and follow-up","volume":"60","author":"Alfaro","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cytox.2019.100005_b0345","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","article-title":"The CXCL8-CXCR1\/2 pathways in cancer","volume":"31","author":"Liu","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0350","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-16-0786","article-title":"CXCL-8\/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL","volume":"77","author":"Manfroi","year":"2017","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cytox.2019.100005_b0355","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/cyto.2002.1994","article-title":"Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera","volume":"20","author":"Hermouet","year":"2002","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0360","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2003-12-4415","article-title":"IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis","volume":"105","author":"Emadi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cytox.2019.100005_b0365","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0370","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ccr.2013.07.018","article-title":"IL-11: a prominent pro-tumorigenic member of the IL-6 family","volume":"24","author":"Grivennikov","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0375","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12013-016-0752-7","article-title":"Interleukin-11: A multifunctional cytokine with intrinsically disordered regions","volume":"74","author":"Permyakov","year":"2016","journal-title":"Cell Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0380","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cyto.2015.08.001","article-title":"Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: A case-control study","volume":"76","author":"Wan","year":"2015","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0385","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2016.01.004","article-title":"The role of IL-11 in immunity and cancer","volume":"373","author":"Xu","year":"2016","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0390","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cytox.2019.100005_b0395","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev.med.45.1.491","article-title":"Tumor necrosis factor: a pleiotropic cytokine and therapeutic target","volume":"45","author":"Tracey","year":"1994","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cytox.2019.100005_b0400","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0405","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.V85.12.3378.bloodjournal85123378","article-title":"Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas","volume":"85","author":"Gruss","year":"1995","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.cytox.2019.100005_b0410","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cytox.2019.100005_b0415","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/RHU.0b013e31821c7ef6","article-title":"Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis","volume":"17","author":"Ong","year":"2011","journal-title":"J. Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0420","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V99.6.2252","article-title":"Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study","volume":"99","author":"Steensma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cytox.2019.100005_b0425","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev.micro.55.1.255","article-title":"Viruses and interferons","volume":"55","author":"Sen","year":"2001","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.cytox.2019.100005_b0430","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev.iy.11.040193.003035","article-title":"The molecular cell biology of interferon-gamma and its receptor","volume":"11","author":"Farrar","year":"1993","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0435","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1359-6101(97)00009-9","article-title":"The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor","volume":"8","author":"Pestka","year":"1997","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0440","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/ehm.12.69","article-title":"Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"6","author":"Silver","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.cytox.2019.100005_b0445","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17474086.2017.1284583","article-title":"Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib","volume":"10","author":"Bj\u00f8rn","year":"2017","journal-title":"Expert Rev. Hematol."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0450","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytox.2019.100005_b0455","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.pathol.2.010506.134925","article-title":"VEGF-A and the induction of pathological angiogenesis","volume":"2","author":"Nagy","year":"2007","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0460","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00109-002-0397-4","article-title":"The role of VEGF in normal and neoplastic hematopoiesis","volume":"81","author":"Gerber","year":"2003","journal-title":"J. Mol. Med."},{"issue":"11","key":"10.1016\/j.cytox.2019.100005_b0465","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0145-2126(02)00053-X","article-title":"Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera","volume":"26","author":"Murphy","year":"2002","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0470","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/BF03033732","article-title":"Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD)","volume":"9","author":"Wr\u00f3bel","year":"2003","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0475","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10245330701554664","article-title":"Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases","volume":"12","author":"Panteli","year":"2007","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0480","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2009.07726.x","article-title":"Angiogenesis and vascular endothelial growth factor-\/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status","volume":"146","author":"Medinger","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0485","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-016-2890-9","article-title":"Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations","volume":"96","author":"Lekovic","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cytox.2019.100005_b0490","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12254-014-0142-z","article-title":"Angiogenesis in myeloproliferative neoplasms, new markers and future directions","volume":"7","author":"Medinger","year":"2014","journal-title":"Memo"},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0495","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.cytox.2019.100005_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081786","article-title":"A review of anti-angiogenic targets for monoclonal antibody cancer therapy","volume":"18","author":"Kong","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytox.2019.100005_b0505","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-beta regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.cytox.2019.100005_b0510","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/jir.2007.0009","article-title":"Transforming growth factor-beta signaling in normal and malignant hematopoiesis","volume":"27","author":"Isufi","year":"2007","journal-title":"J. Interferon Cytokine Res."},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0515","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0520","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1096-8652(199810)59:2<133::AID-AJH6>3.0.CO;2-Z","article-title":"Systemic transforming growth factor-beta in patients with bone marrow fibrosis\u2013pathophysiological implications","volume":"59","author":"Rameshwar","year":"1998","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0525","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1182\/blood.V88.12.4534.bloodjournal88124534","article-title":"Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia","volume":"88","author":"Le Bousse-Kerdil\u00e8s","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0530","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cyto.2010.07.427","article-title":"Evaluation of the bioactive and total transforming growth factor \u03b21 levels in primary myelofibrosis","volume":"53","author":"Campanelli","year":"2011","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.cytox.2019.100005_b0535","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s12032-011-0144-1","article-title":"The relationship of the active and latent forms of TGF-\u03b21 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis","volume":"29","author":"Ponce","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.cytox.2019.100005_b0540","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.humpath.2017.01.007","article-title":"Transforming growth factor \u03b2- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow","volume":"62","author":"Nakayama","year":"2017","journal-title":"Hum. Pathol."},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0545","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.exphem.2016.08.007","article-title":"Preclinical rationale for TGF-\u03b2 inhibition as a therapeutic target for the treatment of myelofibrosis","volume":"44","author":"Ceglia","year":"2016","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0550","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exphem.2006.08.016","article-title":"Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development","volume":"35","author":"Gastinne","year":"2007","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0560","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257453","article-title":"Novel TGF-\u03b2 inhibitors ready for prime time in onco-immunology","volume":"6","author":"de Gramont","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cytox.2019.100005_b0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2017.03.003","article-title":"PDGFs and their receptors","volume":"614","author":"Kazlauskas","year":"2017","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0570","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cytogfr.2014.03.003","article-title":"PDGF receptor signaling networks in normal and cancer cells","volume":"25","author":"Demoulin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0575","first-page":"44","article-title":"Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis","volume":"2","author":"Demoulin","year":"2012","journal-title":"Am. J. Blood Res."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0580","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.1991.tb07952.x","article-title":"Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia","volume":"77","author":"Martyr\u00e9","year":"1991","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.cytox.2019.100005_b0585","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.1991.tb08596.x","article-title":"Interferon-gamma in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia","volume":"77","author":"Martyr\u00e9","year":"1991","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0590","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.1993.tb04624.x","article-title":"Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount, in patients with essential thrombocythaemia","volume":"83","author":"Zauli","year":"1993","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.cytox.2019.100005_b0595","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood.V74.7.2330.2330","article-title":"Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders","volume":"74","author":"Gersuk","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.cytox.2019.100005_b0600","article-title":"The PDGF\/PDGFR pathway as a drug target","author":"Papadopoulos","year":"2017","journal-title":"Mol. Aspects Med."},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0605","first-page":"129","article-title":"Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders","volume":"1","author":"Mesa","year":"2007","journal-title":"Biologics"},{"issue":"2","key":"10.1016\/j.cytox.2019.100005_b0610","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.leukres.2011.09.001","article-title":"Treatment of polycythemia vera with imatinib mesylate","volume":"36","author":"Silver","year":"2012","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0615","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3324\/haematol.2013.102525","article-title":"Imatinib and ruxolitinib association: first experience in two patients","volume":"99","author":"Iurlo","year":"2014","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.cytox.2019.100005_b0620","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1096\/fasebj.3.14.2687068","article-title":"Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines","volume":"3","author":"Wolpe","year":"1989","journal-title":"FASEB J."},{"key":"10.1016\/j.cytox.2019.100005_b0625","first-page":"117","article-title":"Macrophage inflammatory proteins 1 and 2: an overview","volume":"4","author":"Sherry","year":"1992","journal-title":"Cytokines"},{"issue":"6","key":"10.1016\/j.cytox.2019.100005_b0630","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1359-6101(02)00045-X","article-title":"Macrophage inflammatory protein-1","volume":"13","author":"Menten","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0635","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jlb.59.1.61","article-title":"The role of MIP-1 alpha in inflammation and hematopoiesis","volume":"59","author":"Cook","year":"1996","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0640","article-title":"Role of macrophage inflammatory protein (MIP)-1\u03b1\/CCL3 in leukemogenesis","volume":"1","author":"Baba","year":"2014","journal-title":"Mol. Cell. Oncol."},{"issue":"12","key":"10.1016\/j.cytox.2019.100005_b0645","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1182\/blood.V98.12.3476","article-title":"Macrophage inflammatory protein-1alpha uses a novel receptor for primitive hemopoietic cell inhibition","volume":"98","author":"Ottersbach","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytox.2019.100005_b0650","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yjmcc.2009.03.012","article-title":"Macrophage inflammatory protein-1beta induced cell adhesion with increased intracellular reactive oxygen species","volume":"47","author":"Tatara","year":"2009","journal-title":"J. Mol. Cell. Cardiol."}],"container-title":["Cytokine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590153219300047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590153219300047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:35:33Z","timestamp":1762914933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590153219300047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2590153219300047"],"URL":"https:\/\/doi.org\/10.1016\/j.cytox.2019.100005","relation":{},"ISSN":["2590-1532"],"issn-type":[{"value":"2590-1532","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines frequently implicated in myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Cytokine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytox.2019.100005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100005"}}